The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
- Published In:
- Frontiers in endocrinology, 16, 1646956 (2025)
- Authors:
- Zhou, Jingjing, Wang, Fang(2), Li, Sen
- Database ID:
- RPEP-14618
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14618APA
Zhou, Jingjing; Wang, Fang; Li, Sen. (2025). The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.. Frontiers in endocrinology, 16, 1646956. https://doi.org/10.3389/fendo.2025.1646956
MLA
Zhou, Jingjing, et al. "The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.." Frontiers in endocrinology, 2025. https://doi.org/10.3389/fendo.2025.1646956
RethinkPeptides
RethinkPeptides Research Database. "The efficacy and safety of danuglipron and orforglipron in p..." RPEP-14618. Retrieved from https://rethinkpeptides.com/research/zhou-2025-the-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.